Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»277310.25742/NRIPH.2023.03.008Научная статьяCOVID-19 and chronic non-communicable diseases: analysis of data from the Federal Register in the Tomsk regionNaydenovaNadezhda E.nadiet@mail.ruhttps://orcid.org/0000-0002-4085-388XIlyinskikhEkaterina N.infsibgmu@list.ruhttps://orcid.org/0000-0001-7646-6905OstrikovaOlga I.ostrikolga@mail.ruhttps://orcid.org/0000-0002-3147-4044ShilovskayaKsenia Yu.Ksenia28a@gmail.comhttps://orcid.org/0009-0003-5545-6347KomogortsevaKsenia A.ksenya.komogorcev@mail.ruhttps://orcid.org/0009-0005-0354-0488ChenushaDiana S.dianachenusha@gmail.comhttps://orcid.org/0009-0002-6759-6657BoginskayaPolina V.infsibgmu@list.ruhttps://orcid.org/0000-0002-0984-0271SemenovaAlina V.infsibgmu@list.ruhttps://orcid.org/0000-0001-5195-3897Tomsk regional clinical hospitalSiberian State Medical University26052023305052025Copyright © 2025,2025<p>A retrospective analysis of the database of the Federal Register of Persons Patients with a New Coronavirus Infection COVID-19 was performed. All patients (n=369) were hospitalized in the therapeutic departments of the respiratory hospital of the Tomsk Regional Clinical Hospital from November 2020 to January 2021 with a confirmed diagnosis of COVID-19, the presence of pneumonia and with the outcome of the disease recovery. As a result of the study, it was found that the majority of hospitalized patients with COVID-19 (91.3%) had chronic non-communicable diseases with a predominance of diseases of the circulatory system (in 70.7%) and diseases of the endocrine system (in 24.1%). Tendencies of an increase in the duration of hospitalization of patients with the age of patients and in the presence of diseases of the endocrine system were revealed.</p>federal registryCOVID-19chronic noncommunicable diseasespneumoniadiseases of the circulatory systemdiseases of the endocrine system.федеральный регистрCOVID-19хронические неинфекционные заболеванияпневмонииболезни системы кровообращенияболезни эндокринной системы[Drapkina O.M., Karpov O.E., Loukianov M.M., et al. Experience of creating and the first results of the prospective hospital registry of patients with suspected or confirmed coronavirus infection (COVID-19) and community-acquired pneumonia (TARGET-VIP). The Russian Journal of Preventive Medicine. 2020;23(8):6—13. .(in Russian)][Li B., Yang J., Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology 109, 531—538 (2020). https://doi.org/10.1007/s00392-020-01626-9][Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G., et al. International register «Dynamics analysis of comorbidities in SARSCoV-2 survivors» (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Russian Journal of Cardiology. 2021; 26(4):4470. (In Russ.) doi:10.15829/1560-4071-2021-4470. .(in Russian)][Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061—9. doi:10.1001/jama.2020.1585.][Karpova L.S., Stolyarov K.A., Popovtseva N.M., et al. Comparison of the first three waves of the COVID-19 pandemic in Russia in 2020—21. Epidemiology and Vaccinal Prevention. 2022;21(2): 4—16 (In Russ.). https:doi:10.31631/2073-3046-2022-21-2-4-16. .(in Russian)][Boytsov S.A., Martsevich S.Y., Kutishenko N.P., et al. Registers in cardiology: their principles, rules and real-word potential. Cardiovascular Therapy and Prevention. 2013;12(1):4—9.(in Russian)][Martsevich S.Yu., Kutishenko N.P., Lukina Yu.V., Lukyanov M.M., Drapkina O.M. Observational studies and registers. Their quality and role in modern evidence-based medicine. Cardiovascular Therapy and Prevention. 2021;20(2):2786. (In Russ.) doi:10.15829/17288800-2021-2786. .(in Russian)][Konradi A.O., Villevalde S.V., Duplyakov D.V., et al. An open-label multicenter observational study (registry) of patients recovered from coronavirus disease 2019 (COVID-19) with involvement of the cardiovascular system or with baseline severe cardiovascular diseases: rationale, design, and implications for clinical practice. Russian Journal of Cardiology.2021;26(1):4287. .(in Russian)][Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G., et al. International register «Dynamics analysis of comorbidities in SARS-CoV-2 survivors» (AKTIV SARS-CoV-2): analysis of 1,000 patients. Russian Journal of Cardiology. 2020;25(11):4165. .(in Russian)][Fun Q., Zhu H., Zhao J., Zhuang L., Zhang H., Xie H., Zhang R., Granada J.F., Xiang X., Hu W., Yan X. Risk factors for myocardial injury in patients with coronavirus disease 2019 in China. ESC Heart Fail. 2020;10.1002/ehf2.13022. https://doi.org/10.1002/ehf2.13022][Nekaeva E.S., Bolshakova A.E., Malysheva E.S., Galova E.A., Makarova E.V., Nekrasova T.A., Polyakova I.V., Bedretdinova Z.S., Belikina D.V., Lavrenyuk A.A., Fomin I.V. Gender characteristics of the novel coronavirus infection (COVID-19) in middle-aged adults. Sovremennye tehnologii v medicine 2021; 13(4): 16—26, https://doi.org/10.17691/stm2021.13.4.02. .(in Russian)][Molochkov A.V., Karateev D.E., Ogneva E.Yu., Zulkarnaev A.B., Luchikhina E.L., Makarova I.V., Semenov D.Yu. Comorbid diseases and predicting the outcome of COVID-19: results of observation of 13,585 patients who were hospitalized in hospitals in the Moscow region. Almanac of Clinical Medicine. 2020;48(S1):S1–10. doi: 10.18786/2072-0505-2020-48-040. (in Russian)][Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229)][14.:1054—1062. doi: 10.1016/S0140-6736(20)30566—3][Richardson S., Hirsch J.S., Narasimhan M., et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052—2059. doi:10.1001/jama.2020.6775][Casas-Rojo J.M., Antón-Santos J.M., Millán-Núñez-Cortés J., et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry. Rev Clínica Española. English Ed. 2020;220(8):480—94. doi:10.1016/j.][Glybochko P., Fomin V., Avdeev S., et al. Clinical characteristics of 1007 intensive care unit patients with SARS-CoV-2 pneumonia. Clinical pharmacology and therapy. 2020;29(2)][:21—29. (InRuss).] doi: https://doi.org/10.32756/0869-5490-2020-2-21-29. .(in Russian)][Grasselli G., Zangrillo A., Zanella A., et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574—81. doi:10.1001/jama.2020.5394.][Svarovskaya A.V., Shabelsky A.O., Levshin A.V. Charlson comorbidity index in predicting deaths in COVID-19 patients. Russian Journal of Cardiology. 2022;27(3):4711. doi:10.15829/1560-4071-2022-4711. .(in Russian)][Guan W.J., Ni Z.Y., Hu Y., et al. China medical treatment expert group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708−1720. doi: https://doi.org/10.1056/NEJMoa2002032][Jeong I.K., Yoon K.H., Lee M.K. Diabetes and COVID-19: global and regional perspectives. Diabetes Res Clin Pract. 2020; 166: 108303. PMCID: PMC 7332438 PMID: 32623038][Huang I., Lim M.A., Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia — a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395−403. doi: https://doi.org/10.1016/j.dsx.2020.04.018][Tsvetkov V.V., Tokin I.I., Lioznov D.A., Venev E.V., Kulikov A.N. Predicting the duration of inpatient treatment for COVID-19 patients. Meditsinskiy sovet (Medical Council). 2020;(17):82—90. (In Russ.) doi: 10.21518/2079-701X-2020-17-82-90. .(in Russian)][Palaiodimos L., Kokkinidis D.G., Li W., et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262. doi:10.1016/j.metabol.2020.154262.][Mehra M.R., Desai S.S., Kuy S.R., Henry T.D., Patel A.N. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020;382(26):2582. https://doi.org/10.1056/NEJMoa2007621][Nurpeisova A.Kh., Alimova L.K., Ponezheva Zh.B., Mannanova I.V., Popova K.N., Bikmukhametova A.I., Protsenko D.N., Tyurin I.N., Domkina A.M. Clinical and laboratory features of COVID-19 in young people. Lechaschy Vrach. 2021; 3 (24): 45—50. DOI: 10.51793/OS.2021.24.3.009. .(in Russian)]